Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

New biological tools provide new techniques to probe fundamental biological processes.
Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which …

Although we have come a long way in our understanding of the signals that drive cancer
growth, and how these signals can be targeted, effective control of this disease remains a …

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Abstract Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other
second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

Phenotypic and functional heterogeneity arise among cancer cells within the same tumour
as a consequence of genetic change, environmental differences and reversible changes in …

While the understanding of the genomic aberrations that underpin chronic and acute
myeloid leukaemia (CML and AML) has allowed the development of therapies for these …

Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …